Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 8Thoracic 1Head & Neck 1Gynecologic 1Breast 1

Conditions

Triple Negative Breast Neoplasms 3Thyroid Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasm Metastasis 1Lung Neoplasms 1Colonic Neoplasms 1Breast Neoplasms 1Advanced Triple Negative Breast Cancer 1

Interventions

pembrolizumab 29Gemcitabine 16Cyclophosphamide 14Nivolumab 12Carboplatin 12Capecitabine 11Trastuzumab 9Paclitaxel 9Magnetic Resonance Spectroscopy 8Irinotecan 8Bevacizumab 8Albumin-Bound Paclitaxel 8130-nm albumin-bound paclitaxel 8olaparib 7fludarabine 7Docetaxel 7spartalizumab 6aldesleukin 6Drug Therapy 6Cisplatin 6durvalumab 5atezolizumab 5Standard of Care 5Specimen Handling 5Oxaliplatin 5Biopsy 5sargramostim 4palbociclib 4niraparib 4enzalutamide 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Pancreatic Neoplasms × ALT-803 × Breast × Clear all
NCT03127098 2024-08-06

QUILT-3.040: ETBX-011 (Ad5 [E1-, E2b-]-CEA(6D)) Vaccine in Combination With ALT-803 (Super-agonist IL-15) in Subjects Having CEA-Expressing Cancer

NantCell, Inc.

Phase 1/2 Terminated
3 enrolled 6 charts
BreastGastrointestinalGynecologicHead & NeckThoracic

Breast Neoplasms, Colonic Neoplasms, Lung Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms, Thyroid Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡